Clovis Oncology’s CO-1686 Continues to Demonstrate Promising Clinical Activity and Safety in Updated Phase I Study ... Clovis Oncology announced today updated findings from the Phase I portion of its ongoing Phase I/II clinical study of CO-1686, the Company’s novel, oral, targeted covalent inhibitor of mutant forms of the epidermal growth factor receptor for the treatment of non-small cell lung cancer in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M.
Oct. 27, 2013 - Business Wire via Yahoo! Finance
Jim Jagielski in Business Wire (press release) 50% of Covalent customers are clustering their applications, and Covalent engineers are working diligently with them to address the inherent problems when clustering is done at the application level,said Jim Jagielski, CTO of Covalent and...